Q2 Earnings Estimate for GH Research Issued By HC Wainwright

GH Research PLC (NASDAQ:GHRS) – Equities researchers at HC Wainwright dropped their Q2 2026 earnings estimates for shares of GH Research in a note issued to investors on Tuesday, May 19th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.29) per share for the quarter, down from their prior estimate of ($0.26). HC Wainwright currently has a “Buy” rating and a $65.00 price target on the stock. The consensus estimate for GH Research’s current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for GH Research’s Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.21) EPS, Q1 2027 earnings at ($0.35) EPS, Q4 2027 earnings at ($0.47) EPS and FY2027 earnings at ($1.64) EPS.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04).

A number of other equities analysts also recently weighed in on the stock. Citizens Jmp cut their price target on shares of GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a report on Friday, May 15th. Needham & Company LLC boosted their price objective on GH Research from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Cantor Fitzgerald boosted their price objective on GH Research from $25.00 to $35.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Royal Bank Of Canada boosted their price objective on GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Finally, Citigroup restated an “outperform” rating on shares of GH Research in a research note on Friday, May 15th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, GH Research currently has an average rating of “Moderate Buy” and a consensus target price of $40.38.

GH Research Stock Performance

Shares of NASDAQ:GHRS opened at $22.54 on Thursday. The company’s 50-day moving average is $17.52 and its 200 day moving average is $15.72. The company has a market capitalization of $1.55 billion, a P/E ratio of -24.50 and a beta of 1.27. GH Research has a fifty-two week low of $10.66 and a fifty-two week high of $24.66.

Institutional Investors Weigh In On GH Research

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its stake in GH Research by 43.1% in the 1st quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock valued at $36,000 after acquiring an additional 780 shares during the period. Barclays PLC increased its position in shares of GH Research by 63.4% during the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after buying an additional 822 shares during the period. North Star Investment Management Corp. bought a new stake in shares of GH Research during the first quarter valued at about $31,000. Osaic Holdings Inc. increased its position in shares of GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after buying an additional 2,400 shares during the period. Finally, Jefferies Financial Group Inc. increased its position in shares of GH Research by 0.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company’s stock valued at $9,046,000 after buying an additional 2,988 shares during the period. 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.